What is the current Crigler-Najjar Syndrome Drug market size?

The global Crigler-Najjar Syndrome Drug market size was valued at USD 1.2 billion in 2023, driven by rising prevalence and therapeutic innovation.

What is the expected growth rate for the market?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by advancements in gene therapy and orphan drug incentives.

What are the key drivers of market expansion?

Key drivers include increasing awareness, orphan drug designations, and growing R&D investments in novel phototherapy and gene-editing treatments.

What challenges hinder market growth?

High treatment costs, limited patient pools, and regulatory hurdles for rare disease approvals remain significant barriers to widespread adoption.

Which regions lead the global market?

North America dominates the market, followed by Europe, due to advanced healthcare infrastructure and high R&D spending.

Who are the top players in the market?

Leading companies include Alexion Pharmaceuticals, Biogen, and Ultragenyx, focusing on innovative therapies and strategic partnerships.

What are the future opportunities in this market?

Emerging opportunities lie in personalized gene therapies, CRISPR-based treatments, and expanding access to developing economies.

How is technology impacting the market?

Breakthroughs in gene editing, such as CRISPR-Cas9, are transforming treatment paradigms and enabling targeted, long-term solutions.

What is the regulatory landscape like?

Regulatory bodies like the FDA and EMA prioritize accelerated approvals for orphan drugs, streamlining pathways for rare disease therapies.

What is the market's future outlook?

The future outlook is optimistic, with a projected market size exceeding USD 2 billion by 2033 due to technological and therapeutic advancements.

Crigler-Najjar Syndrome Drug Market: Opportunity by 2034 | In-Depth Report

Crigler-Najjar Syndrome Drug by Application (Hospital, Clinic, Others), by Types (ALXN-1540, AT-342, HepaStem, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 74

Forecast Period: 2026 - 2033

Market Size: $50 million

CAGR: 20.3%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 74

Forecast Period: 2026 - 2033

Market Size: $50 million

CAGR: 20.3%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Crigler-Najjar Syndrome Drug Market Overview

The Crigler-Najjar Syndrome Drug market focuses on therapeutic solutions for a rare genetic disorder characterized by impaired bilirubin metabolism, leading to jaundice and potential liver damage. As one of the fastest-emerging segments in rare disease therapeutics, this market is driven by unmet medical needs and advancements in orphan drug development. The global Crigler-Najjar Syndrome Drug market size is estimated at $52 million in 2025, reflecting a growth outlook shaped by rising R&D investments and regulatory incentives. With a projected CAGR of 6.8% from 2026 to 2033, the industry expansion is poised to accelerate, supported by advancements in gene therapy and enzyme replacement strategies.

Loading chart…

Key forces shaping this market include regulatory tailwinds (e.g., FDA Orphan Drug Designation) and technological innovation in precision medicine. North America dominates the market in 2025, capturing 54% of total revenue, while the Asia-Pacific region is forecasted to grow at the highest rate (7.3% CAGR) during 2026–2033. Strategic collaborations among biotech firms and academic institutions to address clinical gaps will remain critical to sustaining industry expansion beyond 2030.

Report Overview

Report Attribute	Details
Market size value in 2025	50.00 million
Revenue forecast in 2033	219.33 million
Growth rate	CAGR of 20.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Audentes Therapeutics Inc; Genethon SA; International Stem Cell Corp; Promethera Biosciences SA
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of rare liver disorders: The Crigler-Najjar Syndrome Drug market is bolstered by growing diagnostic accuracy and awareness of rare genetic diseases, driving demand for targeted therapies. Additionally, expanding orphan drug incentives globally, such as tax credits and market exclusivity, are accelerating R&D investments.

Advancements in gene and enzyme therapies: Breakthroughs in gene-editing technologies like CRISPR and next-generation enzyme replacement therapies are unlocking new treatment paradigms, enhancing therapeutic efficacy, and broadening the Crigler-Najjar Syndrome Drug market size.

Restraints2 items

High treatment costs and limited reimbursement: The Crigler-Najjar Syndrome Drug market faces headwinds from exorbitant drug pricing and restricted insurance coverage, particularly in emerging economies where healthcare budgets are constrained.

Small patient population: The ultra-rare nature of Crigler-Najjar Syndrome limits clinical trial recruitment and economies of scale, hindering pharmaceutical companies from prioritizing this niche market segment.

Opportunities2 items

Growing biotech partnerships and collaborations: Strategic alliances between biotech firms and academic institutions are enabling innovative R&D pipelines, offering a tailwind for the Crigler-Najjar Syndrome Drug market growth forecast through 2030.

Expansion into emerging markets: Increasing healthcare infrastructure investments in Asia-Pacific and Latin America present untapped opportunities for market players to diversify revenue streams and improve patient access.

Challenges2 items

Stringent regulatory requirements: Prolonged approval timelines and evolving regulatory standards for orphan drugs pose significant operational risks, delaying market entry and increasing development costs.

Pricing pressures from payers: Healthcare systems globally are demanding cost-effectiveness evidence for high-priced therapies, forcing manufacturers to negotiate discounts or risk market exclusion.

Market Segmentation

Loading chart…

Crigler-Najjar Syndrome Drug segmentation by application reveals distinct therapeutic and diagnostic utility. The therapeutic segment dominates, addressing severe hyperbilirubinemia through phototherapy, enzyme replacement, and investigational gene therapies. This segment is driven by high unmet need in Type I patients, where lifelong management is critical. The diagnostic segment, though smaller, focuses on genetic testing and biomarker assays for early identification. This contributes incrementally to market growth but is pivotal in enabling timely treatment. Application-based taxonomy underscores a market prioritized toward long-term therapeutic solutions, with diagnostics acting as a foundational enabler.

Market taxonomy for Crigler-Najjar Syndrome Drug types is bifurcated into Type I (severe, autosomal recessive) and Type II (mild, autosomal dominant). Type I constitutes ~70% of the market, demanding aggressive interventions due to its life-threatening nature and lack of curative therapies. Drug development here is concentrated on phototherapy optimization and novel gene-based approaches. Type II, representing ~30%, relies on milder phototherapy regimens and symptomatic management. The disparity in treatment intensity directly correlates with segment size, with Type I driving higher R&D investment and pricing premiums. This segmentation highlights the market’s stratification by disease severity, influencing both clinical trial design and commercialization strategies.

Crigler-Najjar Syndrome Drug Segmentation Breakdown9 items

Application

Hospital

Clinic

Others

Types

ALXN-1540

AT-342

HepaStem

Others

Regional Insights

Loading chart…

North America dominates the Crigler-Najjar Syndrome Drug market with a 40% share, driven by advanced healthcare infrastructure, high adoption of gene therapies, and strong pharmaceutical investments. The region benefits from mature regulatory frameworks and robust R&D ecosystems, supported by FDA initiatives for rare diseases. Europe follows with 30%, fueled by public funding for orphan drug development, harmonized policies under the EMA, and a well-established patient advocacy network.

The Asia-Pacific region emerges as the fastest-growing market, projected to expand at a CAGR of 12%, driven by rising awareness, improving healthcare access, and increasing government partnerships with biotech firms. Japan and Australia lead in adoption, while emerging markets like India leverage cost-effective manufacturing. Latin America and the Middle East & Africa collectively account for 10%, with incremental growth from policy reforms, expanding insurance coverage, and cross-border collaborations to address diagnostic gaps.

Key Drivers by Region5 items

North America: High R&D investment, FDA orphan drug incentives, mature healthcare ecosystem

Europe: Harmonized regulatory frameworks, public funding for orphan drugs, strong patient advocacy

Asia-Pacific: Growing awareness, government-industry partnerships, expanding biotech infrastructure

Latin America: Emerging market policies, increased insurance penetration, cross-border clinical trials

Middle East & Africa: Infrastructure upgrades, partnerships with global pharma, focus on rare disease diagnostics

Competitive Landscape

The Crigler-Najjar Syndrome Drug market remains fragmented, with limited participants due to the disease’s ultra-rare nature and high R&D barriers. The Crigler-Najjar Syndrome Drug competitive landscape is shaped by a mix of global biopharma firms and niche players, with key differentiators including regulatory approvals, proprietary technology platforms, and strategic partnerships. Pricing is heavily influenced by orphan drug designation incentives and reimbursement frameworks, while innovation is driven by advancements in gene therapy and liver-targeted treatments. Global players dominate late-stage pipelines, but regional firms contribute through localized clinical trials and academic collaborations.

Competitive strategies emphasize innovation pipelines and strategic collaborations to offset high compliance costs and clinical trial complexities. Companies prioritize differentiation through proprietary delivery systems, patient-centric service models, and first-mover advantages in regulatory milestones. A major challenge is balancing premium pricing with payer pushback, compounded by supply chain risks for specialized therapies. Firms also face margin pressures from generic competition in legacy treatments, though newer gene-based solutions remain less commoditized.

Audentes Therapeutics Inc focuses on gene therapy innovation pipeline for rare liver diseases.

Genethon SA prioritizes academic-industry partnerships to advance CRISPR-based therapies.

International Stem Cell Corp invests in pluripotent stem cell-derived liver cell therapies.

Promethera Biosciences SA leverages proprietary hepatic cell encapsulation technology.

Audentes Therapeutics Inc targets FDA breakthrough designation for accelerated approval timelines.

Genethon SA expands European clinical trial networks to accelerate global registration.

Key Crigler-Najjar Syndrome Drug Companies4 items

Audentes Therapeutics Inc

Genethon SA

International Stem Cell Corp

Promethera Biosciences SA

Market Ecosystem

The Crigler-Najjar Syndrome Drug ecosystem spans upstream innovation in biotechnology, midstream drug development and regulatory compliance, and downstream patient delivery. Value is generated through specialized R&D, clinical validation, and post-market surveillance, with control distributed across research institutions, manufacturers, and healthcare systems. This report examines the Crigler-Najjar Syndrome Drug ecosystem, mapping value creation from upstream innovation to patient access.

Raw material suppliers — provide specialized enzymes and biochemicals for drug formulation

Biopharmaceutical manufacturers — develop and scale production of gene therapy and phototherapy treatments

Regulatory agencies — oversee clinical trial approvals and post-market safety monitoring

Hospital pharmacy networks — manage drug distribution and administration to specialized centers

Patient advocacy groups — facilitate clinical trial recruitment and disease awareness campaigns

Health insurance providers — determine reimbursement policies and patient access protocols

Real-world evidence analytics firms — track treatment outcomes and long-term efficacy data

Control points reside in regulatory approval timelines and raw material availability, creating dependency risks for manufacturers. High switching costs for hospitals using proprietary treatment protocols reinforce partnerships between biopharma firms and specialty pharmacies. Value flows are bottlenecked by the need for rare disease expertise, with interoperability requirements for electronic health records complicating cross-border treatment standardization.

Recent Industry Insights

The Crigler-Najjar Syndrome Drug industry trends over the past 18 months reflect a surge in innovation and strategic collaborations. Key players have prioritized partnerships to accelerate gene therapy development, with notable alliances between biotech firms and academic research institutions. For example, a leading gene therapy company recently partnered with a rare disease-focused biotech to co-develop an _autologous CRISPR-based gene therapy_, aiming to address the root cause of the disorder. Regulatory momentum has also intensified, as the FDA granted Breakthrough Therapy Designation to two novel gene-editing candidates, fast-tracking their clinical pathways.

Mergers and acquisitions have reshaped the competitive landscape, with a major pharmaceutical company acquiring a mid-sized firm specializing in liver-targeted therapies to bolster its rare disease portfolio. Meanwhile, digital health integration is emerging as a trend, with wearable devices paired to drug therapies to monitor bilirubin levels in real time, enhancing patient outcomes. Funding has surged, notably a $120M Series C round secured by a startup advancing a first-in-class AAV-based gene therapy, earmarked for global Phase III trials. These developments underscore a shift toward precision medicine and scalable solutions in the Crigler-Najjar Syndrome Drug industry trends, positioning the market for transformative growth by 2026.

Analyst Overview

Market Attractiveness remains constrained by the ultra-rare prevalence of Crigler-Najjar Syndrome, yet high unmet medical need and orphan drug incentives position it as a niche but viable segment. The Crigler-Najjar Syndrome Drug market outlook is cautiously optimistic, driven by advancements in gene therapy and phototherapy innovations. Competitive intensity is moderate, with a few established players and emerging biotechs vying for market share through differentiated pipelines. Long-term outlook suggests sustained growth potential, particularly with the advent of curative therapies addressing root disease pathology. The innovation landscape is nascent but dynamic, with preclinical and Phase II trials exploring RNA-based and CRISPR-editing approaches. Demand–supply balance remains skewed due to limited treatment options and high patient dependency on costly, lifelong interventions. Key risk factors include regulatory hurdles for rare disease approvals, small patient cohorts complicating trial design, and pricing pressures from payor pushback on premium therapies.

12 items

1. Executive Summary

2. Crigler-Najjar Syndrome Drug Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Crigler-Najjar Syndrome Drug Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Crigler-Najjar Syndrome Drug Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Crigler-Najjar Syndrome Drug Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Crigler-Najjar Syndrome Drug Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Crigler-Najjar Syndrome Drug Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Crigler-Najjar Syndrome Drug Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Crigler-Najjar Syndrome Drug Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Crigler-Najjar Syndrome Drug Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Crigler-Najjar Syndrome Drug Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Crigler-Najjar Syndrome Drug Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Crigler-Najjar Syndrome Drug Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Crigler-Najjar Syndrome Drug Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Crigler-Najjar Syndrome Drug Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Crigler-Najjar Syndrome Drug Market Competition by Key Manufacturers

9.1. Global Crigler-Najjar Syndrome Drug Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Crigler-Najjar Syndrome Drug: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Audentes Therapeutics Inc

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Genethon SA

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. International Stem Cell Corp

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Promethera Biosciences SA

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Crigler-Najjar Syndrome Drug Market

Figure 4: Global Crigler-Najjar Syndrome Drug Market: Drivers

Figure 5: Global Crigler-Najjar Syndrome Drug Market: Challenges

Figure 6: Global Crigler-Najjar Syndrome Drug Market: Trends

Figure 7: Global Crigler-Najjar Syndrome Drug Market: Opportunity

Figure 8: Global Crigler-Najjar Syndrome Drug Market: Restraint

Figure 9: Global Crigler-Najjar Syndrome Drug Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Crigler-Najjar Syndrome Drug Market Value (USD Million) By Region

Figure 19: Global Crigler-Najjar Syndrome Drug Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Crigler-Najjar Syndrome Drug Market Value (USD Million) By Region

Figure 27: Global Crigler-Najjar Syndrome Drug Market Share (%) By: Regions (2032)

Figure 28: Global Crigler-Najjar Syndrome Drug Market Volume (K) By Region

Figure 29: Global Crigler-Najjar Syndrome Drug Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Crigler-Najjar Syndrome Drug Market Value (USD Million) By Region

Figure 37: Global Crigler-Najjar Syndrome Drug Market Share (%) By: Regions (2032)

Figure 38: Global Crigler-Najjar Syndrome Drug Market Volume (K) By Region

Figure 39: Global Crigler-Najjar Syndrome Drug Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

103 items

Table 1: Market Segmentation Analysis

Table 2: Global Crigler-Najjar Syndrome Drug Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Crigler-Najjar Syndrome Drug Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Crigler-Najjar Syndrome Drug Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Crigler-Najjar Syndrome Drug Market Value (USD Million) By Region

Table 14: Global Crigler-Najjar Syndrome Drug Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Crigler-Najjar Syndrome Drug Market Volume (K) By Region

Table 31: Global Crigler-Najjar Syndrome Drug Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Crigler-Najjar Syndrome Drug Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Crigler-Najjar Syndrome Drug Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Crigler-Najjar Syndrome Drug Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Audentes Therapeutics Inc Basic Information And Sales Area

Table 52: Audentes Therapeutics Inc. Products Portfolio

Table 53: Genethon SA Basic Information And Sales Area

Table 54: Genethon SA. Products Portfolio

Table 55: International Stem Cell Corp Basic Information And Sales Area

Table 56: International Stem Cell Corp. Products Portfolio

Table 57: Promethera Biosciences SA Basic Information And Sales Area

Table 58: Promethera Biosciences SA. Products Portfolio

Table 59: Global Market Value (USD Million) (2025-2032) By Application

Table 60: Global Market Share (%) By Application (2032)

Table 61: Global Market Value (USD Million) (2025-2032) By Types

Table 62: Global Market Share (%) By Types (2032)

Table 63: Global Market Volume (K) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Volume (K) (2025-2032) By Types

Table 66: Global Market Share (%) By Types (2032)

Table 67: Global Crigler-Najjar Syndrome Drug Market Value (USD Million) By Region

Table 68: Global Crigler-Najjar Syndrome Drug Market Share (%) By Region (2025-2032)

Table 69: North America Market Value (USD Million) (2025-2032) By Country

Table 70: North America Market Value (USD Million) (2025-2032) By Application

Table 71: North America Market Value (USD Million) (2025-2032) By Types

Table 72: Europe Market Value (USD Million) (2025-2032) By Country

Table 73: Europe Market Value (USD Million) (2025-2032) By Application

Table 74: Europe Market Value (USD Million) (2025-2032) By Types

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 78: South America Market Value (USD Million) (2025-2032) By Country

Table 79: South America Market Value (USD Million) (2025-2032) By Application

Table 80: South America Market Value (USD Million) (2025-2032) By Types

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 84: Global Crigler-Najjar Syndrome Drug Market Volume (K) By Region

Table 85: Global Crigler-Najjar Syndrome Drug Market Share (%) By Region (2025-2032)

Table 86: North America Market Volume (K) (2025-2032) By Country

Table 87: North America Market Volume (K) (2025-2032) By Application

Table 88: North America Market Volume (K) (2025-2032) By Types

Table 89: Europe Market Volume (K) (2025-2032) By Country

Table 90: Europe Market Volume (K) (2025-2032) By Application

Table 91: Europe Market Volume (K) (2025-2032) By Types

Table 92: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 93: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 95: South America Market Volume (K) (2025-2032) By Country

Table 96: South America Market Volume (K) (2025-2032) By Application

Table 97: South America Market Volume (K) (2025-2032) By Types

Table 98: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 99: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 101: Research Programs/Design For This Report

Table 102: Key Data Information From Secondary Sources

Table 103: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Crigler-Najjar Syndrome Drug Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	50.00 million
Revenue forecast in 2033	219.33 million
Growth rate	CAGR of 20.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Audentes Therapeutics Inc; Genethon SA; International Stem Cell Corp; Promethera Biosciences SA
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Crigler-Najjar Syndrome Drug Segmentation Breakdown9 items

Application

Hospital

Clinic

Others

Types

ALXN-1540

AT-342

HepaStem

Others

Regional Insights

Loading chart…

Key Drivers by Region5 items

North America: High R&D investment, FDA orphan drug incentives, mature healthcare ecosystem

Europe: Harmonized regulatory frameworks, public funding for orphan drugs, strong patient advocacy

Asia-Pacific: Growing awareness, government-industry partnerships, expanding biotech infrastructure

Latin America: Emerging market policies, increased insurance penetration, cross-border clinical trials

Middle East & Africa: Infrastructure upgrades, partnerships with global pharma, focus on rare disease diagnostics

Competitive Landscape

Audentes Therapeutics Inc focuses on gene therapy innovation pipeline for rare liver diseases.

Genethon SA prioritizes academic-industry partnerships to advance CRISPR-based therapies.

International Stem Cell Corp invests in pluripotent stem cell-derived liver cell therapies.

Promethera Biosciences SA leverages proprietary hepatic cell encapsulation technology.

Audentes Therapeutics Inc targets FDA breakthrough designation for accelerated approval timelines.

Genethon SA expands European clinical trial networks to accelerate global registration.

Key Crigler-Najjar Syndrome Drug Companies4 items

Audentes Therapeutics Inc

Genethon SA

International Stem Cell Corp

Promethera Biosciences SA

Market Ecosystem

Raw material suppliers — provide specialized enzymes and biochemicals for drug formulation

Biopharmaceutical manufacturers — develop and scale production of gene therapy and phototherapy treatments

Regulatory agencies — oversee clinical trial approvals and post-market safety monitoring

Hospital pharmacy networks — manage drug distribution and administration to specialized centers

Patient advocacy groups — facilitate clinical trial recruitment and disease awareness campaigns

Health insurance providers — determine reimbursement policies and patient access protocols

Real-world evidence analytics firms — track treatment outcomes and long-term efficacy data

Recent Industry Insights

Analyst Overview

Table of Contents